Jatenzo for Testosterone Deficiency

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Testosterone Deficiency
Jatenzo - Drug
Eligibility
18+
Male
What conditions do you have?
Select

Study Summary

This trial will compare patient satisfaction with Jatenzo, an oral testosterone medication, to other forms of testosterone therapy.

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

2 Primary · 5 Secondary · Reporting Duration: Baseline to 3 months, Baseline to 6 months

6 months
Number of participants reporting preference with the use of Jatenzo
Month 6
Change in PSA levels
Change in estrogen levels
Change in hematocrit levels
Change in low testosterone symptoms as measured by qADAM questionnaire
Change in patient satisfaction as measured by TSQM-9
Change in testosterone levels

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

1 Treatment Group

Jatenzo Arm
1 of 1

Experimental Treatment

40 Total Participants · 1 Treatment Group

Primary Treatment: Jatenzo · No Placebo Group · Phase 4

Jatenzo Arm
Drug
Experimental Group · 1 Intervention: Jatenzo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to 3 months, baseline to 6 months

Who is running the clinical trial?

University of MiamiLead Sponsor
787 Previous Clinical Trials
384,231 Total Patients Enrolled
Clarus TherapeuticsUNKNOWN
2 Previous Clinical Trials
50 Total Patients Enrolled
Ranjith Ramasamy, MDPrincipal Investigator - University of Miami
Univ of Miami Hosp & Clinics-Sylvester Comp Cancer Center, University of Miami Hospital
11 Previous Clinical Trials
1,227 Total Patients Enrolled

Eligibility Criteria

Age 18+ · Male Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You voluntarily sign and date the study consent form(s) which have been approved by an Institutional Review Board (IRB)
You are between 18 and 65 years of age.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 13th, 2021

Last Reviewed: November 30th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
Florida40.0%
Virginia40.0%
South Carolina20.0%
How old are they?
18 - 65100.0%
What site did they apply to?
University of Miami100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria20.0%
Met criteria80.0%

How responsive is this trial?

Typically responds via
Email100.0%
Most responsive sites:
  1. University of Miami: < 24 hours
Average response time
  • < 1 Day